Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. - Wikidata - awgldk - TriplyDB

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

http://www.wikidata.org/entity/Q33763305

about

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

http://www.wikidata.org/entity/Q33763305

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@ast

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@en

type

label

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@ast

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@en

prefLabel

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@ast

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@en

P1433

Q33763305-3E395574-E840-4404-B7DB-94AC3CB35FFA

P1476

Q33763305-51D4A128-EC42-4443-8EC9-92FE9800F095

P2093

Q33763305-08D5E42B-C71B-4745-B69B-F86E55F02B26

Q33763305-0A4C6DAE-86B4-49C7-8927-41F8712883B5

Q33763305-0D833BA9-6585-423B-9186-2F26BC944B5F

Q33763305-140EF401-95AB-4D3A-8170-C27D93AE3922

Q33763305-1C93426A-3411-407C-AA09-01366D818665

Q33763305-302DEA93-4364-4E39-9968-98E5ACC8A56E

Q33763305-30686292-F7A8-4D04-8ADF-A4E28A975B6E

Q33763305-444A0465-B6A1-4071-BE60-110A54191C2D

Q33763305-524185C6-C41C-4E2F-A165-7AE6336FF97F

Q33763305-61FD0426-101B-456E-973F-7F0893327101

P2860

Q33763305-194EF112-A554-45B6-943C-D1EE285D707C

Q33763305-1EF0E426-6C52-4200-ACBB-83322EA4512C

Q33763305-1FC22BF8-E6E6-4D3C-8730-B0E3A3B9BB91

Q33763305-2508B1DB-E80D-4ECC-B1D4-DBFE68160FF9

Q33763305-3451D34F-9FA9-4321-97CA-BB29577FA410

Q33763305-34F3B47F-CEA7-4EA1-B303-BDDD5203E9A3

Q33763305-42968D7C-2C27-4D2A-9297-05E48642ACFA

Q33763305-5A4BF50E-0892-4A79-8FFF-F2F3B43952E0

Q33763305-655ABFB2-94AF-40F3-94DB-0D0B474862FF

Q33763305-88D4C875-8D95-4830-9B00-0AB242A7F73E

P304

Q33763305-E2EDF15F-3079-4746-AC16-1D344AD5AC1D

P31

Q33763305-AC78FF35-7617-4B08-BB79-A25953FD9479

P356

Q33763305-6C418BCE-5429-4F5E-8CAC-A1B745D26B78

P433

Q33763305-75B1598A-5FC1-4347-AA0D-C16007C287EA

P478

Q33763305-92D65901-5583-4590-8F00-90CFFC6DDAF8

P577

Q33763305-60AC2F74-0DD7-4941-AB94-92CE842E2ABA

P698

Q33763305-17B839C7-6ED6-420D-8B0B-F5747C5CF36C

P932

Q33763305-71F0161B-D2E4-4855-B47B-C63C7378D720

P356

P1433

Journal of clinical medicine research

P1476

Ipragliflozin Improves Glycemi ...... With Type 2 Diabetes Mellitus.

@en

P2093

Akira Kanamori

http://www.w3.org/2001/XMLSchema#string

Akira Kubota

http://www.w3.org/2001/XMLSchema#string

Atsuko Mokubo

http://www.w3.org/2001/XMLSchema#string

Fuyuki Minagawa

http://www.w3.org/2001/XMLSchema#string

Hideaki Kaneshige

http://www.w3.org/2001/XMLSchema#string

Hideo Machimura

http://www.w3.org/2001/XMLSchema#string

Hikaru Amemiya

http://www.w3.org/2001/XMLSchema#string

Hiroshi Takeda

http://www.w3.org/2001/XMLSchema#string

Ikuro Matsuba

http://www.w3.org/2001/XMLSchema#string

Kazuaki Shinoda

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

The importance of weight management in type 2 diabetes mellitus.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.

P304

586-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR3038W

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28611859

http://www.w3.org/2001/XMLSchema#string

P932

5458656

http://www.w3.org/2001/XMLSchema#string